Understanding the FDA Draft Guidance on Biosimilar Development and the BPCI Act (Revision 4)
The U.S. Food and Drug Administration (FDA) released New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 4) in March 2026 to clarify regulatory expectations for biosimilar and interchangeable biological products. This draft guidance provides answers to commonly asked questions from industry stakeholders regarding the abbreviated licensure pathway established under Section 351(k) of the Public Health Service (PHS) Act.
The guidance is intended to help pharmaceutical companies, biotechnology firms, and regulatory professionals better understand the regulatory framework for biosimilar development, clinical studies, and application submissions. By providing clarity on scientific and regulatory requirements, the FDA aims to facilitate the development and approval of safe, effective, and high-quality biosimilar products.
For companies developing biosimilars, understanding these updates is essential to ensure compliance with regulatory expectations and to accelerate product development timelines.
Overview of the Biologics Price Competition and Innovation Act (BPCI Act)
The Biologics Price Competition and Innovation Act (BPCI Act) was enacted in 2010 as part of the Affordable Care Act. The law created an abbreviated licensure pathway for biosimilar and interchangeable biological products in the United States.
Under this framework, companies can seek approval for biosimilar products by demonstrating that their product is highly similar to an FDA-licensed reference product and that there are no clinically meaningful differences in safety, purity, and potency.
To obtain approval through the 351(k) Biologics License Application (BLA) pathway, sponsors must submit comprehensive data including:
- Analytical similarity studies
- Nonclinical assessments such as toxicity studies
- Clinical studies evaluating pharmacokinetics (PK), pharmacodynamics (PD), and safety
In certain cases, the FDA may determine that some studies are unnecessary if sufficient evidence is available through analytical and comparative data.
This regulatory pathway promotes market competition and helps increase patient access to biological therapies at potentially lower costs.
Key Regulatory Topics Covered in the Updated FDA Draft Guidance
The latest revision of the FDA draft guidance focuses on several critical regulatory aspects related to biosimilar development. These updates provide clarification on clinical data usage, sample retention requirements, strength demonstration, and regulatory procedures for comparator products.
The key areas addressed include:- Use of non-U.S. licensed comparator products in clinical studies
- Retention of reserve samples used in comparative studies
- Demonstrating equivalent strength for injectable biosimilars
- IND requirements for non-U.S. licensed comparator products
Understanding these elements helps sponsors design regulatory strategies that align with FDA expectations and reduce potential delays during the approval process.
Use of Non-U.S. Licensed Comparator Products in Biosimilar Studies
One of the important clarifications in the draft guidance addresses whether sponsors can use non-U.S. licensed comparator products in clinical studies to support bio similarity.
The FDA indicates that this may be acceptable under certain circumstances. Sponsors must provide sufficient scientific justification demonstrating that the comparator product used in the study is relevant to the U.S.-licensed reference product.
For example, the sponsor should demonstrate:- Structural and functional similarity between the comparator and reference product
- Comparable formulation and inactive ingredients
- Adequate analytical data supporting comparability
Additionally, comparative analytical assessments must include the same lots used in clinical studies to ensure the reliability of biosimilarity conclusions.
Sponsors are encouraged to discuss such development strategies with the FDA early during the product development process to ensure alignment with regulatory expectations.
Retention of Reserve Samples for Biosimilar Clinical Studies
The FDA guidance also provides recommendations regarding the retention of reserve samples used in pharmacokinetic (PK) and pharmacodynamic (PD) studies that support biosimilar applications.
Reserve samples serve several important purposes, including:- Verifying the identity of products used in clinical studies
- Confirming the reliability of study results
- Supporting investigations if additional questions arise after study completion
- Approval of the 351(k) biosimilar application, or
- Completion of the clinical study if the application is not approved.
For most protein therapeutics, sponsors should maintain a minimum of 10 dosage units of each product, ensuring sufficient quantity for advanced analytical testing.
These requirements help ensure transparency, traceability, and reliability of clinical data submitted to the FDA.
Demonstrating Equivalent Strength in Injectable Biosimilars
Another important aspect of biosimilar development is demonstrating that the strength of the proposed biosimilar matches the reference product.
For injectable biosimilars, the FDA generally expects sponsors to demonstrate:- The same total drug substance content as the reference product
- The same concentration of drug substance per unit volume
For biosimilars supplied as dry solids (such as lyophilized powders), sponsors must demonstrate that the total content of the active substance is equivalent to the reference product. After reconstitution, the concentration should also match the reference product.
Sponsors must use the same analytical methods when measuring the strength of both the biosimilar and the reference product, ensuring consistency in the evaluation process.
IND Requirements for Non-U.S. Comparator Products
When a non-U.S. licensed comparator product is imported and used in a clinical study conducted in the United States, the product is considered an investigational new drug (IND).
The FDA allows sponsors to submit a single IND for the entire development program, including studies involving non-U.S. comparator products.
However, sponsors must provide relevant information supporting the clinical investigation, including:- Manufacturing and quality information
- Regulatory approval status in other countries
- Storage and transport conditions
- Labeling and repackaging details
In situations where certain manufacturing information cannot be obtained from the comparator product manufacturer, sponsors may request a regulatory waiver and provide alternative information demonstrating product quality and integrity.
Impact of the FDA Draft Guidance on Biosimilar Development
The updated draft guidance plays an important role in shaping the future of biosimilar development by providing greater clarity on regulatory expectations. It helps pharmaceutical companies design robust development programs while maintaining compliance with FDA requirements.
Key benefits of this guidance include:- Improved regulatory transparency for biosimilar developers
- Clearer expectations for analytical and clinical studies
- Guidance on the use of global comparator products
- Streamlined regulatory pathways for biosimilar approval
These updates ultimately support the growth of the biosimilar market and expand patient access to life-saving biologic therapies.
How Masuu Global Supports Biosimilar Regulatory Compliance
Navigating the complex regulatory landscape of biosimilar development requires deep expertise in global regulatory requirements, clinical strategy, and quality compliance.
Masuu Global provides comprehensive regulatory consulting services to pharmaceutical and biotechnology companies involved in biosimilar development. Our experts support clients with:- Biosimilar regulatory strategy and gap analysis
- FDA and global regulatory submissions
- Biologics License Application (BLA) preparation
- Clinical and analytical documentation support
- Quality and compliance consulting
With a strong understanding of FDA guidance and evolving biosimilar regulations, Masuu Global helps organizations successfully bring biosimilar therapies to market while ensuring regulatory compliance.